Director/PDMR Shareholding

RNS Number : 9256K
GlaxoSmithKline PLC
13 April 2018
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment              

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018.  

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.3940

138

 

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

 

 

 

e)

Date of the transaction

 

2018-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I W Whyte

b)

Position/status

PCA of Mrs V A Whyte (Company Secretary)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018.  

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.3940

645

 

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

e)

Date of the transaction

 

2018-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs D Connor

b)

Position/status

PCA of Mr R G Connor (President, Global Manufacturing & Supply)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018.  

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.3940

342

 
 

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

 

 

 

 

e)

Date of the transaction

 

2018-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHZXLFFVZFZBBK

Companies

GSK (GSK)
UK 100

Latest directors dealings